stockrowOnconetix, Inc.
ONCO Healthcare Biotechnology
Onconetix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $815,400.00, down 67.7% from fiscal 2024.
- Revenue
- −83.9%
- EPS
- +99.5%
- Free cash flow
- −36.0%
Quarter to June 2026, against a year earlier
Follow ONCO
Alert me
Onconetix, Inc. (ONCO) EV/Sales
As of 6 November 2026, Onconetix, Inc. (ONCO) trades at a EV/Sales of 14.6×. Over the past ten years it has ranged from −7.6× (October 2026) to 14.6× (November 2026) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −3.3× | — |
| FY2024 | 1.9× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −5.1× | — |
| Mar 2026 | −3.6× | — |
| Dec 2025 | −3.3× | — |
| Sep 2025 | 3.0× | 55.03% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIPO Lipella Pharmaceuticals Inc. compare | −3.3× |
| TRAW Traws Pharma, Inc. compare | −0.5× |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | 1.5× |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | 8.7× |
| ONCO Onconetix, Inc. | 14.6× |
| ERNA Ernexa Therapeutics Inc. compare | 50.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)